Independent directory Public ClinicalTrials.gov records United States
Clinical Trials Finder
Objective public record navigation
Search Results

Search by objective public record fields.

Search by query text, NCT ID, condition, intervention, sponsor, city, state, recruitment status, phase, study type, healthy volunteer eligibility, sex, or age. Results are retrieved from ClinicalTrials.gov and synchronized into the directory. Search pages remain noindex by default.

Clear filters
ClinicalTrials.gov public records Last synced Sep 23, 2026, 6:28 AM EDT

Data is sourced from official ClinicalTrials.gov public API records. Always review the official ClinicalTrials.gov record for the latest information.

Showing 25–48 of 24 matching trials from the live ClinicalTrials.gov search.
Local D1 index available.
Filters: Intervention: Risperidone Clear all
Completed Phase 2 Interventional Results available

A Trial of the Efficacy and the Safety of RO6889450 (Ralmitaront) vs Placebo in Patients With an Acute Exacerbation of Schizophrenia or Schizoaffective Disorder

NCT04512066
View directory record Official record
Conditions
Schizophrenia, Schizoaffective Disorder
Interventions
RO6889450, Placebo, Risperidone
Drug
Lead sponsor
Hoffmann-La Roche
Industry
Eligibility
18 Years to 45 Years
Enrollment
287 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2020 – 2022
U.S. locations
24
States / cities
Little Rock, Arkansas • Bellflower, California • Culver City, California + 20 more
Source: ClinicalTrials.gov public record
Updated Oct 9, 2023 · Synced Sep 23, 2026, 6:28 AM EDT
Completed Not applicable Interventional Accepts healthy volunteers

Atypical Antipsychotic Treatment Effect On Brain Function In Schizophrenia Measured By FMRI

NCT01234454
View directory record Official record
Conditions
Schizophrenia
Interventions
Risperidone, Olanzapine
Drug
Lead sponsor
University of North Carolina, Chapel Hill
Other
Eligibility
18 Years to 60 Years
Enrollment
34 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2002 – 2007
U.S. locations
1
States / cities
Chapel Hill, North Carolina
Source: ClinicalTrials.gov public record
Updated Apr 2, 2015 · Synced Sep 23, 2026, 6:28 AM EDT
Not listed Not applicable Interventional Accepts healthy volunteers

Glucose Regulation During Risperidone and Olanzapine Treatment

NCT00006195
View directory record Official record
Conditions
Schizophrenia
Interventions
risperidone, olanzapine
Drug
Lead sponsor
National Center for Research Resources (NCRR)
NIH
Eligibility
18 Years to 60 Years
Healthy volunteers
Accepts healthy volunteers
U.S. locations
1
States / cities
St Louis, Missouri
Source: ClinicalTrials.gov public record
Updated Oct 11, 2006 · Synced Sep 23, 2026, 6:28 AM EDT
Completed Early Phase 1 Interventional Accepts healthy volunteers

Reducing the Abuse Liability of Prescription Opioids

NCT04587115
View directory record Official record
Conditions
Addiction
Interventions
Risperidone, Ziprasidone, Oxycodone
Drug
Lead sponsor
The University of Texas Health Science Center at San Antonio
Other
Eligibility
21 Years to 65 Years
Enrollment
15 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2017 – 2020
U.S. locations
1
States / cities
San Antonio, Texas
Source: ClinicalTrials.gov public record
Updated Oct 13, 2020 · Synced Sep 23, 2026, 6:28 AM EDT
Completed Phase 2 Interventional

Study Of Talnetant Versus Placebo And Risperidone In Schizophrenia

NCT00103727
View directory record Official record
Conditions
Schizophrenia
Interventions
Talnetant, placebo, risperidone
Drug · Other
Lead sponsor
GlaxoSmithKline
Industry
Eligibility
18 Years to 65 Years
Enrollment
282 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2004 – 2005
U.S. locations
22
States / cities
Little Rock, Arkansas • Anaheim, California • Cerritos, California + 18 more
Source: ClinicalTrials.gov public record
Updated Apr 28, 2015 · Synced Sep 23, 2026, 6:28 AM EDT
Completed Phase 4 Interventional Accepts healthy volunteers

Pragmatic Trial Comparing Weight Gain in Children With Autism Taking Risperidone Versus Aripiprazole

NCT04903353
View directory record Official record
Conditions
Weight Gain, Autism Spectrum Disorder, Medication Side Effect
Interventions
Comparison of Risperidone and Aripiprazole
Drug
Lead sponsor
Vanderbilt University Medical Center
Other
Eligibility
Up to 17 Years
Enrollment
30 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2022 – 2025
U.S. locations
1
States / cities
Nashville, Tennessee
Source: ClinicalTrials.gov public record
Updated Apr 12, 2026 · Synced Sep 23, 2026, 6:28 AM EDT
Completed Phase 2 Interventional

A Trial of Long-Acting Injectable Risperidone in the Treatment of Methamphetamine Dependence

NCT00284206
View directory record Official record
Conditions
Methamphetamine Dependence
Interventions
long-acting injectable risperidone
Drug
Lead sponsor
Seattle Institute for Biomedical and Clinical Research
Other
Eligibility
18 Years to 65 Years
Enrollment
20 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2006 – 2007
U.S. locations
1
States / cities
Seattle, Washington
Source: ClinicalTrials.gov public record
Updated Jan 10, 2008 · Synced Sep 23, 2026, 6:28 AM EDT
Completed Phase 3 Interventional

Study to Evaluate the Pharmacokinetics (PK) and Safety/Tolerability of Long-Acting Oral LYN-005

NCT05779241
View directory record Official record
Conditions
Schizophrenia, Schizoaffective Disorder
Interventions
LYN-005, Risperidone
Drug
Lead sponsor
Lyndra Inc.
Industry
Eligibility
18 Years to 64 Years
Enrollment
83 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2023
U.S. locations
5
States / cities
Garden Grove, California • Atlanta, Georgia • Chicago, Illinois + 2 more
Source: ClinicalTrials.gov public record
Updated Oct 23, 2024 · Synced Sep 23, 2026, 6:28 AM EDT
Not listed Phase 3 Interventional

Risperidone Augmentation Therapy in Patients Who Have Failed or Only Partially Responded to a Trial of Antidepressant

NCT00174577
View directory record Official record
Conditions
Major Depression
Interventions
Risperidone
Drug
Lead sponsor
Rhode Island Hospital
Other
Eligibility
18 Years to 65 Years
Enrollment
84 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2003 – 2005
U.S. locations
2
States / cities
Atlanta, Georgia • Providence, Rhode Island
Source: ClinicalTrials.gov public record
Updated Sep 14, 2005 · Synced Sep 23, 2026, 6:28 AM EDT
Completed Phase 4 Interventional

Divalproex ER vs. Risperidone for Bipolar Disorder With Comorbid Substance Use Disorder

NCT00203528
View directory record Official record
Conditions
Substance Abuse, Bipolar Depression
Interventions
divalproex sodium ER, risperidone
Drug
Lead sponsor
Tuscaloosa Research & Education Advancement Corporation
Other
Eligibility
19 Years to 65 Years
Enrollment
30 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2004 – 2007
U.S. locations
1
States / cities
Tuscaloosa, Alabama
Source: ClinicalTrials.gov public record
Updated Mar 18, 2007 · Synced Sep 23, 2026, 6:28 AM EDT
Completed Phase 1 Interventional

A Safety and PK Study of Injectable Risperidone-SABER and the DosePro Delivery System in Patients With Schizophrenia

NCT01592110
View directory record Official record
Conditions
Schizophrenia
Interventions
Risperidone-SABER, ZX003:risperidone-SABER and the DosePro System
Drug · Other
Lead sponsor
Zogenix, Inc.
Industry
Eligibility
18 Years and older
Enrollment
40 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2012 – 2013
U.S. locations
1
States / cities
Glendale, California
Source: ClinicalTrials.gov public record
Updated Nov 9, 2022 · Synced Sep 23, 2026, 6:28 AM EDT
Completed Phase 1 Interventional

A Safety and Pharmacokinetic Study of Paliperidone Palmitate in Patients With Schizophrenia

NCT01150448
View directory record Official record
Conditions
Schizophrenia
Interventions
Paliperidone palmitate Treatment A, Paliperidone palmitate Treatment B
Drug
Lead sponsor
Johnson & Johnson Pharmaceutical Research & Development, L.L.C.
Industry
Eligibility
18 Years to 65 Years
Enrollment
212 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2007 – 2009
U.S. locations
5
States / cities
Cerritos, California • National City, California • San Diego, California + 2 more
Source: ClinicalTrials.gov public record
Updated May 27, 2014 · Synced Sep 23, 2026, 6:28 AM EDT
Completed Phase 1 Interventional Results available

Safety, Tolerability, and Pharmacokinetic Study of EVP-6124 in Patients With Schizophrenia

NCT01556763
View directory record Official record
Conditions
Schizophrenia, Schizoaffective Disorder, Central Nervous System Diseases
Interventions
EVP-6124 (0.3 mg/day), EVP-6124 (1.0 mg/day), Placebo, Antipsychotic therapy
Drug
Lead sponsor
FORUM Pharmaceuticals Inc
Industry
Eligibility
18 Years to 55 Years
Enrollment
21 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2008
U.S. locations
1
States / cities
Wichita, Kansas
Source: ClinicalTrials.gov public record
Updated Jun 20, 2012 · Synced Sep 23, 2026, 6:28 AM EDT
Completed Phase 2 Interventional Results available

Use of Galantamine and CDP-choline (Citicoline) to Treat Adults With Schizophrenia

NCT00509067
View directory record Official record
Conditions
Schizophrenia
Interventions
Galantamine, CDP-choline, Placebo, risperidone, olanzapine, quetiapine, ziprasidone, and/or aripiprazole
Drug
Lead sponsor
Georgetown University
Other
Eligibility
18 Years to 70 Years
Enrollment
43 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2007 – 2011
U.S. locations
1
States / cities
Washington D.C., District of Columbia
Source: ClinicalTrials.gov public record
Updated Apr 10, 2018 · Synced Sep 23, 2026, 6:28 AM EDT
Completed Phase 2 Interventional

Risperidone Treatment in Dually-Diagnosed Individuals - 2

NCT00000267
View directory record Official record
Conditions
Cocaine-Related Disorders
Interventions
Risperidone
Drug
Lead sponsor
National Institute on Drug Abuse (NIDA)
NIH
Eligibility
18 Years to 60 Years
Healthy volunteers
Healthy volunteers not accepted
Timeline
Ends 2001
U.S. locations
1
States / cities
New York, New York
Source: ClinicalTrials.gov public record
Updated Jan 11, 2017 · Synced Sep 23, 2026, 6:28 AM EDT
Completed Phase 2Phase 3 Interventional Results available

Pharmacogenomics in Autism Treatment

NCT00584701
View directory record Official record
Conditions
Autism
Interventions
Risperidone
Drug
Lead sponsor
University of California, San Francisco
Other
Eligibility
4 Years to 18 Years
Enrollment
49 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2008 – 2009
U.S. locations
1
States / cities
San Francisco, California
Source: ClinicalTrials.gov public record
Updated Jul 23, 2012 · Synced Sep 23, 2026, 6:28 AM EDT
Completed Phase 2 Interventional

Depakote ER Plus an Atypical Antipsychotic Vs. an Atypical Antipsychotic Alone in the Treatment of Schizophrenia

NCT00073164
View directory record Official record
Conditions
Schizophrenia
Interventions
Divalproex Sodium Extended-Release Tablets, Olanzapine, Risperidone
Drug
Lead sponsor
Abbott
Industry
Eligibility
18 Years to 65 Years
Enrollment
400 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
Started 2003
U.S. locations
35
States / cities
Birmingham, Alabama • Tuscaloosa, Alabama • Anaheim, California + 32 more
Source: ClinicalTrials.gov public record
Updated Aug 3, 2006 · Synced Sep 23, 2026, 6:28 AM EDT
Completed Phase 4 Interventional Results available

Study to Measure Drug Satisfaction of Patients With Schizophrenia After Switching From Risperidone to Paliperidone

NCT00535132
View directory record Official record
Conditions
Schizophrenia
Interventions
Oral Risperidone, Paliperidone ER
Drug
Lead sponsor
Johnson & Johnson Pharmaceutical Research & Development, L.L.C.
Industry
Eligibility
18 Years and older
Enrollment
201 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2007 – 2008
U.S. locations
15
States / cities
Cerritos, California • Garden Grove, California • Huntington Beach, California + 12 more
Source: ClinicalTrials.gov public record
Updated May 8, 2014 · Synced Sep 23, 2026, 6:28 AM EDT
Completed Not applicable Interventional

Antidepressant and Antipsychotic to Treat Attenuated Positive and Negative Symptoms

NCT00169988
View directory record Official record
Conditions
Prodromal Schizophrenia, Psychotic Disorders
Interventions
risperidone, sertraline-primary
Drug
Lead sponsor
Northwell Health
Other
Eligibility
12 Years to 22 Years
Enrollment
8 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2004 – 2007
U.S. locations
1
States / cities
Glen Oaks, New York
Source: ClinicalTrials.gov public record
Updated Dec 16, 2009 · Synced Sep 23, 2026, 6:28 AM EDT
Completed Phase 2 Interventional

Treating Behavioral Disturbances in Individuals With Dementia

NCT00073658
View directory record Official record
Conditions
Dementia
Interventions
Citalopram, Risperidone
Drug
Lead sponsor
University of Pittsburgh
Other
Eligibility
50 Years and older
Enrollment
137 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2000 – 2005
U.S. locations
1
States / cities
Pittsburgh, Pennsylvania
Source: ClinicalTrials.gov public record
Updated Mar 9, 2014 · Synced Sep 23, 2026, 6:28 AM EDT
Completed Phase 3 Interventional

Switch Study of Existing Atypical Antipsychotics to Bifeprunox

NCT00347425
View directory record Official record
Conditions
Schizophrenia and Schizoaffective Disorder
Interventions
Aripiprazole, Olanzapine, Risperidone, Quetiapine, Ziprasidone
Drug
Lead sponsor
Solvay Pharmaceuticals
Industry
Eligibility
18 Years to 65 Years
Enrollment
286 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2006 – 2008
U.S. locations
63
States / cities
Birmingham, Alabama • Little Rock, Arkansas • Anaheim, California + 54 more
Source: ClinicalTrials.gov public record
Updated May 20, 2008 · Synced Sep 23, 2026, 6:28 AM EDT
Completed Not applicable Interventional

Specific Interventions for Agitation in Alzheimer's Disease

NCT00018291
View directory record Official record
Conditions
Alzheimer's Disease, Dementia
Interventions
Risperidone, Gabapentin
Drug
Lead sponsor
US Department of Veterans Affairs
Federal
Eligibility
50 Years and older
Healthy volunteers
Healthy volunteers not accepted
Timeline
2001 – 2005
U.S. locations
1
States / cities
Menlo Park, California
Source: ClinicalTrials.gov public record
Updated Jan 20, 2009 · Synced Sep 23, 2026, 6:28 AM EDT
Completed Phase 1 Interventional

Single Ascending Dose Study of RBP-7000

NCT02768649
View directory record Official record
Conditions
Schizophrenia
Interventions
RBP-7000, risperidone
Drug
Lead sponsor
Indivior Inc.
Industry
Eligibility
18 Years to 65 Years
Enrollment
45 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2011 – 2012
U.S. locations
1
States / cities
Willingboro, New Jersey
Source: ClinicalTrials.gov public record
Updated May 10, 2016 · Synced Sep 23, 2026, 6:28 AM EDT
Completed Phase 2 Interventional Results available

Safety and Efficacy of Cariprazine (RGH-188) in the Acute Exacerbation of Schizophrenia

NCT00694707
View directory record Official record
Conditions
Schizophrenia
Interventions
Placebo, Cariprazine, Risperidone
Drug
Lead sponsor
Forest Laboratories
Industry
Eligibility
18 Years to 60 Years
Enrollment
732 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2008 – 2009
U.S. locations
18
States / cities
Costa Mesa, California • Long Beach, California • Oceanside, California + 14 more
Source: ClinicalTrials.gov public record
Updated Jun 11, 2019 · Synced Sep 23, 2026, 6:28 AM EDT